Estudio de resultados cardiovasculares MK-0616

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The

El estudio VALOR

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16. The primary hypothesis is Vericiguat is superior

Estudio de pembrolizumab/vibostolimab en combinación con quimiorradioterapia concurrente seguida de pembrolizumab/vibostolimab frente a quimiorradioterapia concurrente seguida de durvalumab en participantes con cáncer de pulmón de células no pequeñas en estadio III

This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab versus cCRT followed by durvalumab in participants with unresectable, locally